About: COVID-19 pandemic and therapy with ibuprofen or renin-angiotensin system blockers: no need for interruptions or changes in ongoing chronic treatments

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: COVID-19 pandemic and therapy with ibuprofen or renin-angiotensin system blockers: no need for interruptions or changes in ongoing chronic treatments Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	COVID-19 pandemic and therapy with ibuprofen or renin-angiotensin system blockers: no need for interruptions or changes in ongoing chronic treatments
Creator	Hafner, Susanne Schmidt, Christoph Zolk, Oliver
Source	Medline; PMC
abstract	Scientists hypothesized that drugs such as ibuprofen or renin-angiotensin system (RAS) blockers could exacerbate the novel coronavirus disease COVID-19 by upregulating the angiotensin-converting enzyme 2 (ACE2), which serves as an entry receptor for the coronavirus SARS-CoV-2. This hypothesis was taken up by the lay press and led to concerns among doctors and patients whether the use of these drugs was still safe and justified against the background of the pandemic spread of SARS-CoV-2 with an increasing number of cases and deaths. In this article, we summarize what is known about the effect of RAS blockers or non-steroidal anti-inflammatory drugs (NSAIDs) on the course of COVID-19 disease. In the case of RAS inhibition, we also find evidence for the opposite hypothesis, namely, that RAS inhibition in COVID-19 could be protective. In view of the inconsistent and limited evidence and after weighing up the benefits and risks, we would not currently recommend discontinuing or switching an effective treatment with RAS blockers. NSAIDs should be used at the lowest effective dose for the shortest possible period. The choice of drug to treat COVID-19-associated fever or pain should be based on a benefit-risk assessment for known side effects (e.g., kidney damage, gastrointestinal ulceration).
has issue date	2020-05-15(xsd:dateTime)
bibo:doi	10.1007/s00210-020-01890-6
bibo:pmid	32415494
has license	cc-by
sha1sum (hex)	8d63da106f0f4f85aef2f43d4701b0fdd58e6f68
schema:url	https://doi.org/10.1007/s00210-020-01890-6
resource representing a document's title	COVID-19 pandemic and therapy with ibuprofen or renin-angiotensin system blockers: no need for interruptions or changes in ongoing chronic treatments
has PubMed Central identifier	PMC7225250
has PubMed identifier	32415494
schema:publication	Naunyn Schmiedebergs Arch Pharmacol
resource representing a document's body	covid:8d63da106f0f4f85aef2f43d4701b0fdd58e6f68#body_text
is schema:about of	named entity 'Scientists' named entity 'SARS-CoV-2' named entity 'COVID' named entity 'ongoing' named entity 'CONCERNS' named entity 'PAIN' named entity 'EVIDENCE FOR' named entity 'WEIGHING' named entity 'RAS' named entity 'ibuprofen' named entity 'number' named entity 'hypothesis' named entity 'assessment' named entity 'gastrointestinal' named entity 'blockers' named entity 'effective dose' named entity 'drugs' named entity 'effective' named entity 'effective dose' named entity 'RAS' named entity 'NSAIDs' named entity 'SARS-CoV-2' named entity 'angiotensin-converting enzyme 2' named entity 'receptor' named entity 'ibuprofen' named entity 'ibuprofen' named entity 'ACE inhibitors' named entity 'TMPRSS2' named entity 'antiviral activity' named entity 'ibuprofen' named entity 'prognosis' named entity 'probability' named entity 'angiotensin' named entity 'ACE inhibitors' named entity 'lung' named entity 'spike (S) protein' named entity 'coronavirus' named entity 'ACE inhibitor' named entity 'COVID' named entity 'ACE2' named entity 'SARS-CoV-2' named entity 'NSAIDs' named entity 'critically ill' named entity 'kidney' named entity 'comorbidities' named entity 'AT1' named entity 'ACE2' named entity 'hypertension' named entity 'SARS-CoV-2' named entity 'lung function' named entity 'host cell' named entity 'multiple organ failure' named entity 'renin-angiotensin' named entity 'biologically active' named entity 'recombinant' named entity 'RAS' named entity 'gas exchange' named entity '2009 H1N1 influenza pandemic' named entity 'heart failure' named entity 'COVID-19' named entity 'COVID' named entity 'SARS-CoV-2' named entity 'COVID-19.' named entity 'phase 1' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'recombinant' named entity 'COVID' named entity 'hydrolyzes' named entity 'coronavirus disease' named entity 'ARBs' named entity 'inflammation' named entity 'inflammation' named entity 'receptor' named entity 'SARS-CoV-2' named entity 'World Health Organization' named entity 'inflammatory response' named entity 'alveolar' named entity 'Pneumonia'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software